According to the ACOG clinical guideline: management of cervical cytology and histological abnormalities. Women 21 years and older should be followed up with HPV-DNA screening every 12 months or repeat cytology at 6 and 12 months. Decisions about treatment do not depend on satisfactory colposcopy results, and treatment is not recommended in the first 2 years of follow-up. If CIN1 has not resolved after 2 years, resection or ablative therapy is feasible if colposcopic findings are satisfactory. For patients who decide to treat, if colposcopic findings are unsatisfactory, if the cervical canal specimen has CIN, or if the patient has had previous treatment, ablative therapy is not indicated and diagnostic hysterectomy is recommended. The management of CIN1 in adolescents is the same as for adolescent LSIL. histologic diagnosis of CIN1 in pregnant women is recommended for follow-up without treatment. Pregnant women should not be treated for CIN1.